Pharmacogenomics of depression

Alessandro Serretti, Antonio Drago, Edoardo Spina

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Pharmacotherapy of depression is characterized by poor predictability of individual response. In addition to pathophysiological and environmental factors, genetic factors appear to play an important role in determining differences in treatment outcome of antidepressant drugs (ADs). In recent years, a number of pharmacogenetic studies have been conducted on ADs, and genetic variations at the level of drug-metabolizing enzymes, drug transporters and drug targets that may influence the clinical response have been identified. Hopefully, pharmacogenetics will provide the basis for individualized pharmacotherapy of depressive disorders in order to maximize the probability of a favorable response and to minimize the risk of adverse drug reactions. In this chapter, the major findings related to the pharmacogenetics of genes involved in the pharmacokinetics and pharmacodynamics of ADs are critically reviewed.

Original languageEnglish
Title of host publicationPharmacogenomics in Psychiatry
PublisherS. Karger AG
Pages58-74
Number of pages17
Volume25
ISBN (Print)9783805594998, 9783805594981
DOIs
Publication statusPublished - Jun 25 2010

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Serretti, A., Drago, A., & Spina, E. (2010). Pharmacogenomics of depression. In Pharmacogenomics in Psychiatry (Vol. 25, pp. 58-74). S. Karger AG. https://doi.org/10.1159/000317299